Today, Martin Shkreli, the reviled former pharmaceutical CEO best known for price-gouging a life-saving drug, running an alleged Ponzi-like scheme, and smirking, had the date for his trial on securities fraud charges set to June 26, 2017 in New York.

Shkreli, 33, has been indicted on eight charges in connection with the alleged Ponzi-like scheme, in which he swindled his former pharmaceutical company, Retrophin, out of $11 million in order to cover and hide losses from two hedge funds he managed. He was arrested back in December along with his former counsel, Evan Greebel. Both have pled not guilty to all charges and Shkreli was released on $5 million bail that he posted with an E-trade account worth $45 million at the time.

Since then, the pair have had their court proceedings delayed after Shkreli fired his legal team and federal prosecutors added additional charges.

In today’s hearing in Brooklyn, US District Judge Kiyo Matsumoto finally set the trial date and Shkreli’s new attorney, Ben Brafman, told the judge that Shkreli is likely to pursue a reliance of counsel defense. Brafman has mentioned this in past hearings. This defense strategy would essentially try to pin any wrong doing on Greebel.

As such, Shkreli will likely seek a separate trial from Greebel, who is also likely to ask for a separate trial.

"I don't think there's a finger of blame to point in this case,” Brafman told reporters after today’s hearing. “You know, to the extent that both defendants may be innocent — and one is a lawyer and our client relied on his advice — doesn't necessarily mean that either of them committed a crime. It may mean that they both cannot have a joint trial, however."

If the two are tried separately, Matsumoto said that the second trial would take place October 2, 2017. However, she did not specify which defendant would be tried first.

To many, Shkreli has already been tried and found guilty in the court of public opinion for raising the price of the life-saving drug, Daraprim, by more than 5,000 percent. He orchestrated that price hike as the head of Turing Pharmaceuticals, which he founded in 2015 after being fired in 2014 from Retrophin, another pharmaceutical company he founded. Shkreli has been unapologetic about the price increase as well as resolute about his innocence in the fraud case. In past court and congressional hearings, the ex-CEO has smirked, mocked, and laughed at federal lawmakers and prosecutors. In today’s trial, he stayed quiet and raised eyebrows. Afterward, according to New York Daily News, he asked Brafman, “Can I go play Pokémon now?”